Top 100 Events Social Events A discussion on the advancement of CAR T-cell therapies for B-cell-derived hematologic malignancies and the challenges facing cell therapy development in solid tumors due to the hostile tumor microenvironment...
COHA is the trusted cancer treatment center that has been providing comprehensive hematology-oncology services throughout the community of Columbia, Stevensville, Glen Burnie, and Annapolis, Maryland, for more than 25 years.
In hematologic oncology, acute myeloid leukemia (AML) presents a significant challenge due to its complex genetic landscape and resistance to conventional therapies. Despite advances in treatment, including intensive chemotherapy and hematopoietic stem cell transplantation (HSCT), the prognosis for many pati...
Targeted protein degradation in recent decades has emerged as a revolutionary therapeutic strategy in oncology. Prototypical immunomodulatory imide drugs (IMiDs) including thalidomide, lenalidomide, and pomalidomide, are widely used in the treatment of various hematological cancers such as multiple myeloma (...
Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10. Article PubMed Google Scholar Golovina TN, Vonderheide RH. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer J. 2010;16:342–7. Article CAS PubMed Google Scholar Sojka DK, Huang YH, ...
Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China. As of August 28, 20
it introduces commonly used thrombus scoring scales in internal medicine, oncology, and surgical patients, analyzing and comparing their advantages and disadvantages. Finally, it discusses the current application of AI in thrombotic diseases, the challenges faced at this stage, and potential directions fo...
Acute myeloid leukemia (AML) is a genetically heterogeneous clonal malignancy characterized by recurrent gene mutations. Genomic heterogeneity, patients’ individual variability, and recurrent gene mutations are the major obstacles among many factors tha
Nanopharmacology in translational hematology and oncology Ciprian Tomuleasa,1,2,* Cornelia Braicu,1,* Alexandra Irimie,3 Lucian Craciun,1 Ioana Berindan-Neagoe1,4,51Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Ha
Vida Oncology is a medical practice located in Shelbyville, IN that specializes in Medical Oncology with Dr. Jaime Ayon as the Medical Director. Outpatient cancer care and blood disorders is our focus. Hematology Oncology Doctors near me.